Matthew Cohen, DO
Pain Medicine · Charlotte, MINPI 1508081787
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,196 of the $5,122 with a category attached, or 81.9%. It is spread thinly across 34 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,284, 2.1 times the $623 reported in 2019.
Across 201 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Saluda Medical Americas, Inc.$911
- SPR Therapeutics, Inc$705
- Collegium Pharmaceutical, Inc.$668
- Abbott$389
- Boston Scientific$288
- Teva Pharmaceuticals USA, Inc.$216
- plus $2K from 28 others
What the payments were for
- Travel & lodging$92518%
- Food & beverage$4,19682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Saluda Medical Americas, Inc. | 3 | $911 |
| SPR Therapeutics, Inc | 8 | $705 |
| Collegium Pharmaceutical, Inc. | 44 | $668 |
| Abbott | 16 | $389 |
| Boston Scientific | 6 | $288 |
| Teva Pharmaceuticals USA, Inc. | 14 | $216 |
| Lilly USA, LLC | 14 | $203 |
| GRT US Holding, Inc. | 10 | $174 |
| Averitas Pharma Inc. | 9 | $169 |
| Biodelivery Sciences International, Inc. | 11 | $167 |
| AbbVie | 8 | $151 |
| Pfizer | 9 | $145 |
| Amgen | 7 | $121 |
| Vertos Medical, Inc. | 6 | $102 |
| Vertex | 5 | $93 |
| Nevro Corp. | 3 | $85 |
| Medtronic(2 entities) | 4 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $66 |
| Vertiflex, Inc. | 1 | $58 |
| Avanos Medical | 3 | $45 |
| Novartis | 2 | $34 |
| MDD US Operations, LLC | 2 | $30 |
| Assertio Therapeutics, Inc. | 2 | $30 |
| Stryker | 1 | $29 |
| Painteq LLC | 1 | $24 |
| Spinal Simplicity, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Nalu Medical, Inc. | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Bioventus LLC | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evoke$911
- SPRINT PNS System$634
- Proclaim DRG IPG$128
How this compares
$5,122 in reported general payments places this provider in the 65th percentile of 139 pain medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 14 | $12,621 |
| BelbucaBuprenorphine Hcl | 15 | $11,409 |
| Buprenorphine | 41 | $9,983 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $9,980 |
| OxycontinOxycodone Hcl | 13 | $8,351 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 189 | $6,035 |
| Fentanyl | 32 | $4,132 |
| Lubiprostone | 12 | $2,849 |
| Lidocaine | 18 | $2,277 |
| Gabapentin | 134 | $2,238 |
| Pregabalin | 134 | $1,601 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 90 | $1,417 |
| Morphine Sulfate ErMorphine Sulfate | 38 | $1,300 |
| Duloxetine Hcl | 52 | $1,255 |
| Tizanidine Hcl | 42 | $792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $668 | $24,03029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 139 pain medicine providers in Michigan.
Other pain medicine in Charlotte
- Harry SukumaranRochester Hills$304K
- Nasir KhatriFlint$133K
- Yijia ChuGrand Rapids$88K
- Mark MounayerSouthfield$85K
- Jeffrey RosenbergCanton$44K
- Alexander TurfeWyandotte$41K
- Kendall GroseWyandotte$26K
- Craig HartrickRoyal Oak$26K
- Patrick ForrestAnn Arbor$23K
- Anmar DalatiDetroit$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.